These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New York State and drug lists: a history of confusion. Stetler CJ Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687 [No Abstract] [Full Text] [Related]
5. Striving for standards in bioequivalence assessment: a review. Schulz HU; Steinijans VW Int J Clin Pharmacol Ther Toxicol; 1991 Aug; 29(8):293-8. PubMed ID: 1743802 [No Abstract] [Full Text] [Related]
6. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
8. Who really assures prescription drug quality? J Indiana State Med Assoc; 1979 Mar; 72(3):164. PubMed ID: 422862 [No Abstract] [Full Text] [Related]
9. Benefits and liabilities of generic prescribing. Lee AM W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384 [No Abstract] [Full Text] [Related]
10. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality? Marsh DA; Hoar ME Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245 [TBL] [Abstract][Full Text] [Related]
11. Multinational medicines--ensuring drug quality in an era of global manufacturing. Okie S N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686 [No Abstract] [Full Text] [Related]
12. Biopharmaceutic equivalency and the role of the Food & Drug Administration. Hodges RM Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859 [No Abstract] [Full Text] [Related]
13. Major events during the generic drug investigations. Am Pharm; 1990 Jul; NS30(7):38-9. PubMed ID: 2363392 [No Abstract] [Full Text] [Related]
14. Some thoughts on the generic equivalency debate. Berry FB Med Times; 1971 Sep; 99(9):199-201. PubMed ID: 5170858 [No Abstract] [Full Text] [Related]
19. [Bioequivalence of solid drug preparation]. Ejima A Eisei Shikenjo Hokoku; 1982; (100):1-20. PubMed ID: 6897833 [No Abstract] [Full Text] [Related]
20. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint. Ley HL; Desmond FH Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100 [No Abstract] [Full Text] [Related] [Next] [New Search]